Pharma & Biotech Strategy Consulting, Business Plans & Fundraising Support

Whether you are just starting out or trying to evolve an established life science business, today’s investors are more aware than ever that sound strategy is essential. A mix of R&D productivity pressure, tightening regulations, scientific innovation and a market demanding value evidence is challenging companies to think carefully about their goals and priorities. Our life science consultants have rich experience in strategic planning with companies at all stages of corporate development.

  • Craft a business case for company strategy
  • Develop your corporate pitch deck for investors
  • Prioritize R&D spending through portfolio review and pipeline planning
  • Build a business unit or technology strategy plan

Both external investors and internal sponsors in a business draw confidence from quality business planning and can tell whether a business plan or strategy is realistic. Our subject matter experts have launched, grown, and sold companies. They have successfully raised capital and advised investors and company boards about funding decisions. Let us help you consider all relevant strategic options for your business or your pipeline, analyze them thoroughly, and present a clear and well-reasoned case that your strategy is the right one.

 

Biotech strategy consulting & business planning case studies

Case Study: Business plan for medical device start-up

Challenge: Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan with which to engage investors. Alacrita was asked to review and refine the business plan, with a particular emphasis on the target market, product value proposition, and market access plan.

Solution: Our consultant prioritized the target patient segments and settings of care for the device, framed the value proposition around the needs of key market stakeholders, and aligned these with the company's clinical development and market access plans. Our consultants brought direct experience in the commercialization of prescription opioids, deep knowledge of the opioid crisis and an expertise in developing and launching medical devices in the US market.

Our expert and investor network was able to sanity check further the plan for the device and its value proposition. The business plan review resulted in the client changing their clinical development and investment staging plans. Based on its importance to investors and payers, the client framed its clinical proof-of-concept plans around showing that the device could give an early enough warning to deliver on its value proposition.


Case Study: Business planning on cancer immunotherapy and valuations for a new start-up

Challenge: An established cancer immunotherapy company needed help with a business plan and valuation for a new company to be setup in collaboration with a major US cancer center
With this requirement now fairly urgent, Alacrita was asked to develop a high-level infrastructural plan integrating all of these elements. Based on this, and further validation of the market access plans, the biopharma company also wanted a clear go-to-launch plan to realize the best possible launch for its product. In order to align the launch on a global basis and ensure successful launches in both the US and Europe, the company also wanted the supply chain outlined in the context of their planned US organizational structure.

Solution: We provided critical review of numerous drafts of the business plan and were asked by our client to write the commercialization and pricing sections of the business plan.  We then developed risk adjusted NPV valuations for three different programs, each of which took an autologous, cell-based multi-epitope approach. We incorporated Monte Carlo simulations into the financial model to account for real-world uncertainty, given these programs were early stage and there were numerous questions about development costs and future product sales. Our Monte Carlo model was able to accommodate uncertainties around clinical trial duration, sales growth scenarios and sales decline scenarios. The business plan and valuation models were key supporting documents as the new company marketed the opportunity to prospective venture investors.


Case Study: Corporate pitch deck for investors

Challenge: A start-up US biotech developing a non-opioid analgesic drug and delivery device was preparing to raise its first round of external funding. They engaged Alacrita to help frame the target market for their product and to communicate the commercial opportunity to investors in their pitch deck.

Solution: Led by a consultant with direct experience of commercializing new pain management products in the US market, Alacrita prioritized potential target patient segments within the pain management space, by type of pain and setting of care. In each case, we framed the size of the opportunity, and related the product value proposition to the unmet medical needs and burden of disease. We also discussed with the client, possible applications for their product in management of opioid addiction.

Once a set of go-to-market priorities had been agreed with the client, Alacrita built a slide deck for communication with prospective investors, utilizing our experience in framing business cases for this target audience.